Oral Antiviral

Oral Antiviral Market Outlook

The global oral antiviral market has been valued at approximately USD 27 billion in 2022, with a projected compound annual growth rate (CAGR) of around 7.5% from 2023 to 2035. This indicates a robust growth trajectory influenced by the rising prevalence of viral infections and the increasing demand for effective antiviral therapies. The market is further bolstered by advancements in pharmaceutical research, leading to the development of new oral antiviral drugs, which are easier for patients to administer compared to traditional intravenous therapies. Increasing healthcare expenditure and awareness regarding the importance of timely treatment are also pivotal in propelling market growth. Additionally, the COVID-19 pandemic has heightened the focus on antiviral medications, fostering innovations in drug formulation and delivery mechanisms.

Growth Factor of the Market

The growth of the oral antiviral market is significantly driven by the increasing incidence of viral infections, such as influenza, HIV, and hepatitis, which necessitates effective treatment options. Additionally, the global rise in healthcare accessibility and the push for affordable treatment options contribute to market expansion. The shift towards home healthcare and self-medication is also propelling the demand for oral antiviral medications, as they offer convenience and ease of use. Moreover, the substantial investment in research and development by pharmaceutical companies has led to the emergence of novel oral antiviral agents, which have demonstrated enhanced efficacy and safety profiles. Furthermore, the growing aging population, which is more susceptible to viral infections, is expected to further elevate the demand for oral antiviral medications in the coming years.

Key Highlights of the Market

• Projected market size of USD 45 billion by 2035.
• Significant growth driven by the rise in viral infections and advanced drug formulations.
• Expanding online pharmacies enhancing accessibility to oral antiviral medications.
• Increased collaboration between pharmaceutical companies and healthcare providers.
• Growing investment in antiviral research leading to innovative therapies.

By Product Type

Tablets :

Tablets represent one of the leading product types in the oral antiviral market, primarily due to their convenience and ease of administration. They are often favored by both healthcare providers and patients for their precise dosage and extended shelf life. The increasing prevalence of viral infections has led to a surge in demand for tablet formulations, particularly for chronic conditions such as HIV and hepatitis. Furthermore, advancements in tablet technology, including controlled-release formulations, have improved patient compliance and treatment efficacy. Major pharmaceutical companies are actively pursuing research to enhance the therapeutic efficacy of existing tablet-based antiviral drugs, thereby expanding their market presence.

Capsules :

Capsules are another significant segment within the oral antiviral market, appreciated for their ability to mask unpleasant tastes and improve the overall patient experience. They are often preferred for potent antiviral agents that require precise dosing, such as oseltamivir, which is widely used for the treatment of influenza. The flexible formulation options available for capsules allow for the incorporation of various ingredients, enhancing the bioavailability and effectiveness of the medication. Additionally, the trend towards personalized medicine has led to an increase in demand for capsule formulations tailored to individual patient needs, further driving the market growth for this segment.

Suspensions :

Suspensions are particularly beneficial for patients who have difficulty swallowing tablets or capsules, such as children or the elderly. This segment, although smaller than tablets and capsules, is gaining traction due to the increased focus on patient-friendly formulations. Oral suspensions allow for dosing flexibility, enabling healthcare providers to adjust dosages according to patient requirements. The growth of the pediatric patient population requiring antiviral therapy has also played a crucial role in the expansion of this market segment, prompting pharmaceutical companies to develop more suspension formulations to cater to this demographic. Moreover, the rising prevalence of respiratory virus infections has led to an increased focus on developing effective suspension-based antiviral therapies.

Syrups :

Syrups are particularly prominent in the oral antiviral market intended for pediatric use, as they provide a palatable alternative to solid dosage forms. The sweetness of syrup formulations often makes them more acceptable to children, which is crucial for ensuring compliance in antiviral treatment regimens. This segment is significantly benefitting from the increasing incidence of viral infections in children, hence driving demand for effective antiviral options. Additionally, syrup formulations allow for easy administration and accurate dosing, which further enhances their appeal in pediatric care. As the focus on children's health continues to grow, the syrup segment is likely to witness substantial growth in the upcoming years.

Lozenges :

Lozenges serve as a unique segment in the oral antiviral market, particularly effective for the symptomatic relief of viral infections affecting the throat, such as those caused by herpes simplex virus. They allow for localized action and are often formulated with antiviral agents that can provide relief from sore throat and discomfort. This delivery form is gaining popularity due to its convenience and the ease of use it provides, especially among individuals seeking quick relief from infectious symptoms. The increasing demand for over-the-counter medications that are easy to administer and provide symptomatic relief is likely to bolster the growth of the lozenge segment further.

By Application

Herpes Simplex Virus :

Herpes simplex virus (HSV) infections remain a significant public health concern, leading to a substantial demand for oral antivirals specifically targeting this virus. Treatments for HSV primarily focus on managing symptoms and reducing outbreaks, which has driven the development of effective oral antiviral medications such as acyclovir. The growing awareness of sexually transmitted infections (STIs) and the need for prompt treatment options are propelling the market for HSV-targeting antivirals. Moreover, ongoing research into combination therapies aimed at enhancing treatment efficacy is expected to further drive growth in this application segment.

Influenza :

Influenza remains a major contributor to global morbidity and mortality, significantly impacting the demand for oral antiviral medications. The seasonal flu outbreaks underscore the need for effective treatment options to reduce the duration and severity of symptoms. Antivirals like oseltamivir have become standard treatments for influenza, leading to their widespread use. The increasing frequency of influenza pandemics, combined with the push for preventive measures, is expected to sustain growth in this segment. Additionally, the development of novel antiviral agents specifically targeting influenza strains is likely to contribute positively to the market landscape.

HIV :

The application of oral antivirals in the treatment of HIV has become a critical component of global health strategies aimed at managing the virus and preventing transmission. The availability of effective oral antiviral regimens has revolutionized the treatment landscape for HIV patients, allowing for improved adherence and quality of life. The demand for novel antiviral therapies that offer enhanced efficacy, reduced side effects, and once-daily dosing is on the rise, propelling market growth. Furthermore, awareness campaigns and initiatives aimed at increasing HIV testing and treatment access are likely to significantly contribute to the expansion of this application segment.

Hepatitis :

Hepatitis infections, particularly hepatitis B and C, pose a considerable healthcare challenge worldwide, leading to increased demand for effective oral antiviral treatments. These infections often go undetected for years, highlighting the need for widespread screening and immediate treatment post-diagnosis. Oral antiviral medications, such as ribavirin and direct-acting antivirals (DAAs), have been instrumental in achieving sustained virologic response rates, thereby transforming hepatitis management. The growing awareness of hepatitis and the focus on eliminating the virus through accessible treatment options are expected to drive further growth in this application segment.

Respiratory Syncytial Virus :

Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in children and the elderly, creating a notable market for oral antiviral medications targeting this virus. The increasing prevalence of RSV infections, particularly in pediatric populations, necessitates the development of effective treatment options to mitigate severe disease outcomes. While preventive measures such as vaccines are still in development, antiviral therapies like ribavirin are gaining attention due to their utility in managing RSV infections. The rising incidence of RSV infections and the subsequent demand for effective antiviral medications will likely drive the growth of this application segment.

By Distribution Channel

Hospital Pharmacies :

Hospital pharmacies play a critical role in the distribution of oral antiviral medications, particularly for patients requiring immediate and comprehensive care. These pharmacies are often staffed by specialized pharmacists who ensure accurate dispensing and provide essential counseling on medication use. The growing number of hospital admissions due to viral infections is expected to boost the demand for oral antivirals dispensed through hospital pharmacies. Additionally, hospitals increasingly collaborate with pharmaceutical companies to obtain the latest antiviral drugs, further propelling the growth of this distribution channel.

Retail Pharmacies :

Retail pharmacies represent a significant distribution channel for oral antiviral medications due to their accessibility and convenience for patients. These establishments offer a wide range of antiviral medications, catering to both prescription and over-the-counter needs. The increasing prevalence of viral infections has led to higher patient footfall in retail pharmacies, driving demand for effective antiviral treatments. Furthermore, the rise of chain pharmacies and pharmacies located in grocery stores has improved accessibility, allowing more patients to obtain their medications without the need for hospital visits. The competitive pricing strategies adopted by retail pharmacies are also enhancing their appeal, thus contributing to the growth of this segment.

Online Pharmacies :

The emergence of online pharmacies has transformed the oral antiviral market, providing patients with convenient access to medications. The digitalization of healthcare has led to a surge in online pharmacy services, allowing patients to order prescribed antiviral medications from the comfort of their homes. This growth has been fueled by the increasing preference for remote healthcare services, particularly among younger generations. Online pharmacies offer the advantage of discreet purchasing, competitive pricing, and home delivery, making them appealing to a vast patient demographic. Additionally, the COVID-19 pandemic has accelerated the adoption of online pharmacies, further solidifying their position in the oral antiviral market.

Drug Stores :

Drug stores serve as an essential distribution channel for oral antiviral medications, providing easy access to a broad spectrum of healthcare products. These establishments often stock both prescription and over-the-counter antiviral medications, catering to different patient needs. The convenience of drug stores, often located within communities, allows individuals to obtain medications without extensive travel. The rise in self-medication trends has increased the demand for antiviral drugs available at drug stores, contributing to the growth of this channel. Furthermore, promotional offers and loyalty programs instituted by drug stores enhance customer engagement and retention, driving sales in this segment.

Clinics :

Clinics, particularly outpatient facilities, are becoming increasingly important in the distribution of oral antiviral medications, providing accessible treatment options for patients with viral infections. These establishments often focus on specific health concerns, such as infectious diseases, allowing for specialized care and management of antiviral therapies. The rise in walk-in clinics and urgent care centers has contributed to the increased distribution of oral antivirals, enabling timely treatment for patients presenting with viral symptoms. Moreover, collaborations between clinics and pharmaceutical companies facilitate the availability of the latest antiviral agents, further enhancing their role in the oral antiviral market.

By Ingredient Type

Acyclovir :

Acyclovir remains a cornerstone in the oral antiviral market, particularly for the treatment of herpes virus infections, including herpes simplex and varicella-zoster virus. It is recognized for its efficacy in reducing the severity and duration of outbreaks, making it a vital therapeutic option. The established safety profile and availability of generic formulations of acyclovir contribute to its widespread use. Ongoing research into combination therapies involving acyclovir aims to enhance its effectiveness and broaden its therapeutic applications, potentially driving future market growth.

Oseltamivir :

Oseltamivir is a widely recognized antiviral medication employed primarily for the treatment and prevention of influenza. Its efficacy in reducing the duration and severity of flu symptoms has made it a staple in antiviral therapy, particularly during seasonal outbreaks. The increasing prevalence of influenza and the rise in public health initiatives aimed at improving vaccination and treatment compliance have bolstered the demand for oseltamivir. Additionally, research into its effectiveness against emerging influenza strains could further enhance its market position, ensuring its relevance in antiviral treatment protocols.

Zanamivir :

Zanamivir serves as a critical antiviral agent for managing influenza, especially in cases where oseltamivir may not be suitable. While its delivery method via inhalation presents unique challenges, zanamivir has shown significant efficacy in treating influenza virus infections. The growing need for alternative antiviral options during flu outbreaks is anticipated to drive the demand for zanamivir in the oral antiviral market. Furthermore, ongoing studies focusing on its effectiveness against different strains of influenza are likely to enhance its market presence.

Ribavirin :

Ribavirin is an essential antiviral medication used primarily in the treatment of chronic hepatitis C and some viral infections, such as respiratory syncytial virus. Its combination with other antiviral agents has significantly improved treatment outcomes for hepatitis patients, making it a critical component of antiviral therapy protocols. The increasing global burden of hepatitis infections has underscored the need for effective treatments, positioning ribavirin favorably within the oral antiviral market. As research continues into its potential applications in treating other viral infections, ribavirin's relevance in the market is expected to persist.

Abacavir :

Abacavir is a prominent nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV infections. Its effectiveness in suppressing viral replication has made it a key component of highly active antiretroviral therapy (HAART) for HIV patients. The growing focus on improving treatment adherence and the emergence of fixed-dose combinations incorporating abacavir have further solidified its position in the oral antiviral market. The continuous research into abacavir's safety and efficacy, particularly in diverse patient populations, is likely to sustain its relevance and demand in the upcoming years.

By Region

The North American region dominates the oral antiviral market, accounting for approximately 40% of the global share in 2022. The high prevalence of viral infections and advanced healthcare infrastructure significantly contribute to the region's market dominance. Furthermore, the presence of leading pharmaceutical companies and extensive research activities aimed at developing innovative antiviral solutions bolster the market landscape in this region. The North American market is expected to maintain a steady CAGR of around 6.5% through 2035, driven by increasing healthcare expenditures and heightened focus on antiviral treatments resulting from recent public health crises.

In Europe, the oral antiviral market is projected to experience significant growth, driven by a combination of factors, including increasing awareness of viral infections and supportive healthcare policies promoting access to antiviral treatments. The European market is expected to contribute approximately 30% of the global market share by 2035, buoyed by a growing aging population and rising incidences of chronic viral infections such as hepatitis and HIV. Additionally, the increasing collaboration between healthcare providers and pharmaceutical companies to enhance treatment access and affordability is anticipated to propel market growth in the European region.

Opportunities

The oral antiviral market presents numerous opportunities for growth, particularly through the development of novel antiviral agents that target emerging viral infections. As new viral strains continue to emerge, the demand for effective antiviral treatments is expected to rise, prompting pharmaceutical companies to invest in research and development. Collaborations between academia and industry can foster innovation, leading to the discovery of new therapeutic targets and enhanced drug formulations. Furthermore, the increasing focus on personalized medicine and tailored antiviral therapies presents significant opportunities for companies to cater to diverse patient populations, ensuring better therapy adherence and outcomes.

Another opportunity lies in the expansion of distribution channels, particularly through online pharmacies and telehealth services. The COVID-19 pandemic has accelerated the adoption of digital healthcare solutions, allowing patients to access antiviral medications with greater ease. Pharmaceutical companies can leverage this trend by enhancing their online presence and forging partnerships with telehealth platforms to ensure broader access to their products. Additionally, the growing interest in preventive healthcare measures and vaccination campaigns may lead to increased awareness and demand for antiviral medications, further driving market growth in the upcoming years.

Threats

The oral antiviral market faces potential threats that may impede growth, particularly the emergence of antiviral resistance. The prolonged and widespread use of antiviral medications can lead to the development of resistant viral strains, diminishing the effectiveness of existing treatments. This poses a significant challenge for healthcare providers and pharmaceutical companies, necessitating ongoing research to develop new antiviral agents capable of overcoming resistance mechanisms. Additionally, regulatory hurdles and stringent approval processes for new antiviral medications may delay market entry and limit the availability of innovative treatment options.

Moreover, the high costs associated with research and development of new antiviral drugs can pose a restraining factor for smaller pharmaceutical companies. The significant investment required for clinical trials and obtaining regulatory approvals may deter new entrants into the market, leading to reduced competition and innovation. Furthermore, economic fluctuations and public health policies can impact healthcare budgets, subsequently affecting the funding available for antiviral research and development, limiting the growth potential of the oral antiviral market.

Competitor Outlook

• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AbbVie Inc.
• Roche Holding AG
• Johnson & Johnson
• ViiV Healthcare Limited
• Novartis AG
• Sanofi S.A.
• AstraZeneca plc
• Hetero Labs Limited
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.

The competitive landscape of the oral antiviral market is characterized by the presence of numerous well-established pharmaceutical companies and emerging players striving to innovate and capture market share. The market dynamics are driven by continuous research and development efforts, with companies focusing on enhancing the efficacy and safety profiles of their antiviral products. Collaborations and strategic partnerships between pharmaceutical companies and healthcare providers are becoming increasingly common, enabling better distribution and access to antiviral medications. Moreover, the entry of generics is also intensifying competition, as these products often provide more affordable alternatives for patients, thereby influencing market pricing strategies.

Major companies such as Gilead Sciences, Inc. continue to lead the oral antiviral market through their extensive portfolios of antiviral medications, particularly in HIV and hepatitis treatment. Gilead's commitment to research and innovation has resulted in the development of groundbreaking therapies that improve patient outcomes. Similarly, Merck & Co., Inc. is recognized for its contributions to the influenza antiviral landscape, particularly with oseltamivir. The company's ongoing research efforts aim to enhance treatment protocols for viral infections, which further solidifies its position in the market.

Companies like AbbVie Inc. and Bristol-Myers Squibb Company are also making significant strides in the oral antiviral market through their investments in antiviral research programs and the introduction of novel therapies targeting various viral infections. AbbVie has positioned itself as a leader in hepatitis C treatments, while Bristol-Myers Squibb continues to innovate in the HIV space, focusing on combination therapies that improve treatment adherence. The competitive landscape remains dynamic, with established players constantly evolving their strategies to maintain their market leadership positions while addressing emerging challenges in the oral antiviral sector.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Mylan N.V.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hetero Labs Limited
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 ViiV Healthcare Limited
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 F. Hoffmann-La Roche Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bristol-Myers Squibb Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Oral Antiviral Market, By Application
    • 6.1.1 Herpes Simplex Virus
    • 6.1.2 Influenza
    • 6.1.3 HIV
    • 6.1.4 Hepatitis
    • 6.1.5 Respiratory Syncytial Virus
  • 6.2 Oral Antiviral Market, By Product Type
    • 6.2.1 Tablets
    • 6.2.2 Capsules
    • 6.2.3 Suspensions
    • 6.2.4 Syrups
    • 6.2.5 Lozenges
  • 6.3 Oral Antiviral Market, By Ingredient Type
    • 6.3.1 Acyclovir
    • 6.3.2 Oseltamivir
    • 6.3.3 Zanamivir
    • 6.3.4 Ribavirin
    • 6.3.5 Abacavir
  • 6.4 Oral Antiviral Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Clinics

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Oral Antiviral Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Oral Antiviral market is categorized based on

By Product Type

• Tablets
• Capsules
• Suspensions
• Syrups
• Lozenges

By Application

• Herpes Simplex Virus
• Influenza
• HIV
• Hepatitis
• Respiratory Syncytial Virus

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Clinics

By Ingredient Type

• Acyclovir
• Oseltamivir
• Zanamivir
• Ribavirin
• Abacavir

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AbbVie Inc.
• Roche Holding AG
• Johnson & Johnson
• ViiV Healthcare Limited
• Novartis AG
• Sanofi S.A.
• AstraZeneca plc
• Hetero Labs Limited
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.